NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
- State
- Completed
- Phase
- Phase 2 and Phase 3
- People
- 351 taking part
- Started
- 1 Apr 2023
- Primary completion
- 13 Feb 2024
- Arms
- 7.5mg Buntanetap/Posiphen, 15mg Buntanetap/Posiphen, 30mg Buntanetap/Posiphen
- Results
- Posted on the registry
- 17 Jan 2023: Trial registered
- 1 Apr 2023: Trial started
- 13 Feb 2024: Trial completed
- 29 Apr 2025: Trial results posted